BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 29121201)

  • 1. High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma.
    Mazziotti G; Formenti AM; Frara S; Olivetti R; Banfi G; Memo M; Maroldi R; Giubbini R; Giustina A
    J Clin Endocrinol Metab; 2018 Mar; 103(3):956-964. PubMed ID: 29121201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
    J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
    Sijanovic S; Karner I
    Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women.
    Fujiyama K; Kiriyama T; Ito M; Kimura H; Ashizawa K; Tsuruta M; Nagayama Y; Villadolid MC; Yokoyama N; Nagataki S
    Thyroid; 1995 Feb; 5(1):13-7. PubMed ID: 7787427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of thyroid stimulating hormone suppressive therapy on bone geometry in the hip area of patients with differentiated thyroid carcinoma.
    Moon JH; Jung KY; Kim KM; Choi SH; Lim S; Park YJ; Park DJ; Jang HC
    Bone; 2016 Feb; 83():104-110. PubMed ID: 26518742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma.
    Heijckmann AC; Huijberts MS; Geusens P; de Vries J; Menheere PP; Wolffenbuttel BH
    Eur J Endocrinol; 2005 Jul; 153(1):23-9. PubMed ID: 15994742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study.
    Pedersini R; Monteverdi S; Mazziotti G; Amoroso V; Roca E; Maffezzoni F; Vassalli L; Rodella F; Formenti AM; Frara S; Maroldi R; Berruti A; Simoncini E; Giustina A
    Bone; 2017 Apr; 97():147-152. PubMed ID: 28104509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women.
    Baqi L; Payer J; Killinger Z; Hruzikova P; Cierny D; Susienkova K; Langer P
    Endocr Regul; 2010 Apr; 44(2):57-63. PubMed ID: 20429634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.
    Panico A; Lupoli GA; Fonderico F; Marciello F; Martinelli A; Assante R; Lupoli G
    Thyroid; 2009 May; 19(5):437-42. PubMed ID: 19415993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vertebral fracture prevalence among Greek healthy middle-aged postmenopausal women: association with demographics, anthropometric parameters, and bone mineral density.
    Lambrinoudaki I; Flokatoula M; Armeni E; Pliatsika P; Augoulea A; Antoniou A; Alexandrou A; Creatsa M; Panoulis C; Dendrinos S; Papacharalambous X
    Spine J; 2015 Jan; 15(1):86-94. PubMed ID: 25106754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
    Marcocci C; Golia F; Vignali E; Pinchera A
    J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density.
    Mazziotti G; Porcelli T; Patelli I; Vescovi PP; Giustina A
    Bone; 2010 Mar; 46(3):747-51. PubMed ID: 19892039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.
    Diamond T; Nery L; Hales I
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1184-8. PubMed ID: 2026740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Reverter JL; Holgado S; Alonso N; Salinas I; Granada ML; Sanmartí A
    Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma.
    Florkowski CM; Brownlie BE; Elliot JR; Ayling EM; Turner JG
    N Z Med J; 1993 Oct; 106(966):443-4. PubMed ID: 8233173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of TSH Suppression on Vertebral Trabecular Bone Scores in Patients With Differentiated Thyroid Carcinoma.
    Moon JH; Kim KM; Oh TJ; Choi SH; Lim S; Park YJ; Park DJ; Jang HC
    J Clin Endocrinol Metab; 2017 Jan; 102(1):78-85. PubMed ID: 27754806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-year estimated risk of bone fracture in women with differentiated thyroid cancer under TSH-suppressive levothyroxine therapy.
    Vera L; Gay S; Campomenosi C; Paolino S; Pera G; Monti E; Mortara L; Seriolo B; Giusti M
    Endokrynol Pol; 2016; 67(4):350-8. PubMed ID: 27387240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy.
    De Mingo Dominguez ML; Guadalix Iglesias S; Martin-Arriscado Arroba C; López Alvarez B; Martínez Diaz-Guerra G; Martinez-Pueyo JI; Ferrero Herrero E; Hawkins Carranza F
    Endocrine; 2018 Oct; 62(1):166-173. PubMed ID: 30014437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study.
    Sugitani I; Fujimoto Y
    Surgery; 2011 Dec; 150(6):1250-7. PubMed ID: 22136848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabecular bone score in women with differentiated thyroid cancer on long-term TSH-suppressive therapy.
    Sousa BÉCA; Silva BC; de Oliveira Guidotti T; Pires MC; Soares MMS; Kakehasi AM
    J Endocrinol Invest; 2021 Oct; 44(10):2295-2305. PubMed ID: 33730348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.